

System, resulting in 100% follow-up. However, we are looking into retrieving secondary endpoints such as cardiovascular mortality and, based on intuition, we think this will further improve the prognostic strength of GLS in our cohort.

Morten Sengeløv, MB*
Peter Godsk Jørgensen, MD
Jan Skov Jensen, MD, PhD, DMSc, MD
Niels Eske Bruun, MD, DMSc
Flemming Javier Olsen, MB
Thomas Fritz-Hansen, MD
Kotaro Nochioka, MD, PhD
Tor Biering-Sørensen, MD, PhD

*Department of Cardiology
Gentofte Hospital
University of Copenhagen, Denmark
Kildegårdsvej 28, DK-2900, Post 835, Copenhagen
Denmark
E-mail: jlm392@alumni.ku.dk
<http://dx.doi.org/10.1016/j.jcmg.2016.01.006>

Please note: This study was financially supported by the Danish Council for Independent Research. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

REFERENCES

1. Sengeløv M, Jørgensen PG, Jensen JS, et al. Global longitudinal strain is a superior predictor of all-cause mortality in heart failure with reduced ejection fraction. *J Am Coll Cardiol Img* 2015;8:1351-9.
2. Biering-Sorensen T, Hoffmann S, Mogelvang R, et al. Myocardial strain analysis by 2-dimensional speckle tracking echocardiography improves diagnostics of coronary artery stenosis in stable angina pectoris. *Circ Cardiovasc Imaging* 2014;7:58-65.
3. Yang H, Marwick TH, Fukuda N, et al. Improvement in strain concordance between two major vendors after the strain standardization initiative. *J Am Soc Echocardiogr* 2015;28:642-8.

One Good Friend Is Better Than Many



We have read with great interest the paper by Prati et al. (1) on the CLI-OPLI II study (Centro per la Lotta

contro l'Infarto-Optimisation of Percutaneous Coronary Intervention). The newly defined *suboptimal stent deployment* was associated with an increased risk of major adverse cardiac events. Since the evidence to support the clinical benefit of optical coherence tomography (OCT) during percutaneous coronary intervention (PCI) remains limited, this study provides important information about its use for stent deployment. However, we would like to draw attention to the data presented in the CLI-OPLI II study, especially regarding baseline characteristics and definitions of suboptimal OCT stent deployment.

First, the combination of many conditions obfuscates the interpretation of results. Patients with different clinical presentations (stable ischemic heart disease and an acute coronary syndrome) and different types of stents (i.e., bare-metal stent, drug-eluting stent, and bioabsorbable vascular scaffold) were included. Since in other studies, PCI guidance using imaging has been beneficial mostly in acute coronary syndrome (2) (i.e., ST-segment elevation myocardial infarction), and each device has a different neointimal growth pattern and extent, it is difficult to draw any conclusion from this report.

Second, the parameters for suboptimal stent deployment are too many to be measured and interpreted online in the catheterization laboratory. The authors suggested 6 significant factors that had different weightings. Conversely, in the most recent published IVUS-XPL (Impact of Intravascular Ultrasound Guidance on Outcomes of Xience Prime Stents in Long Lesions) trial, the authors chose only 1 IVUS criterion for stent optimization after PCI (3). This latter simple approach is easier to adopt and implement in clinical practice.

Third, the definition of suboptimal OCT stent deployment has been changed (Table 1), despite the authors' claim: "The aim of the present study was to assess the impact of these pre-specified OCT

	CLI-OPLI I	CLI-OPLI II	XPL IVUS
In-stent MLA	≥90% of average reference lumen area or ≥100% of lumen area of reference segment with lowest lumen area	<70% of average reference lumen area or in-stent minimum or lumen area (MLA) <4.5 mm ²	MLA greater than lumen area at distal reference segment
Edge dissection	Linear rim of tissue with width ≥200 μm	Linear rim of tissue with width ≥200 μm	
Reference lumen narrowing	Lumen area <4.0 mm ²	Lumen area <4.5 mm ²	
Malapposition	Stent-adjacent vessel lumen distance >200 μm	Stent-adjacent vessel lumen distance >200 μm	
Intrastent plaque/thrombus protrusion	Intraluminal mass ≥200 μm in thickness	Intraluminal mass ≥500 μm in thickness	

CLI-OPLI = Centro per la Lotta contro l'Infarto-Optimisation of Percutaneous Coronary Intervention; MLA = minimal lumen area.

quantitative criteria (CLI OPCI I study) on clinical outcomes after PCI” (4). It would be a great contribution to the field if the authors would present an analysis similar to that of the XPL study (considering only 1 criterion, minimal lumen area greater than the lumen area at the distal reference segment) to present a simplified approach that could be easily embraced in clinical practice.

Sang Yeub Lee, MD, PhD

Ron Waksman, MD

Hector M. Garcia-Garcia, MD, PhD*

*MedStar Washington Hospital Center

110 Irving Street, NW, Suite 4B-1

Washington, DC 20010

E-mail: hector.m.garciagarcia@medstar.net

<http://dx.doi.org/10.1016/j.jcmg.2016.01.012>

Please note: Dr. Waksman has reported relationships with Biotronik, Medtronic, AstraZeneca, Boston Scientific, Abbott Vascular, The Medicines Company, St. Jude Medical, Biosensors International, and Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

REFERENCES

1. Prati F, Romagnoli E, Burzotta F, et al. Clinical impact of OCT findings during PCI: the CLI-OPCI II study. *J Am Coll Cardiol Img* 2015;8:1297-305.
2. Witzenzichler B, Maehara A, Weisz G, et al. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) study. *Circulation* 2014;129:463-70.

3. Hong S-J, Kim B-K, Shin D-H, et al. Effect of intravascular ultrasound-guided vs angiography-guided everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. *JAMA* 2015;314:2155-63.

4. Prati F, Di Vito L, Biondi-Zoccai G, et al. Angiography alone versus angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention: the Centro per la Lotta contro l’Infarto-Optimisation of Percutaneous Coronary Intervention (CLI-OPCI) study. *EuroIntervention* 2012;8:823-9.

THE AUTHORS REPLY:



The main advantage of optical coherence tomography (OCT) resides in its ability to identify issues that may be missed by intravascular ultrasound (IVUS); however, OCT may provide operators with an excess of information that may lead to an overreaction, in an effort to correct innocent but ominous-looking anatomic issues.

The CLI-OPCI (Centro per la Lotta contro l’Infarto-Optimisation of Percutaneous Coronary Intervention) II study (1) was specifically designed to answer these crucial questions in “everyday” practice and therefore included a heterogeneous population, with demographic, clinical, and procedural differences. Importantly, the CLI-OPCI project was conceived years ago to gather OCT data from more centers, year by year, with the goal of refining our understanding

